MacroGenics, Inc.

NASDAQ:MGNX

Biotechnology

Healthcare
$1.97 +2.02%

+$0.08 today

Market cap
$125.90M
Beta
1.20
P/E (TTM)
-3.6
EPS (TTM)
-$1.11
52W Low $1.19High $4.64

Volume 0.72M

Average 0.98M

MGNX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

MacroGenics, Inc.NASDAQ: MGNX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of $9.56M rose 58.7% year over year, ahead of the +16.2% change in trailing-twelve-month gross profit. Sequentially, it fell 67.5% from the prior quarter. Over 3 fiscal years it compounded at -9.3% a year.

Context

  • Gross profit amounted to 71.1% of revenue in FY2025, down 20.6 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +58.7% holds above the trailing-twelve-month pace of +16.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.56M-67.5% QoQ
Last fiscal yearDec 2025
$106.32M-21.8% YoY
LTMMar 2026
$109.85M+16.2% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58.7%——
1 year-21.8%——
3-year CAGR-9.3%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
106.32M USD
Year-over-year change
-21.8%
4-year CAGR
+9.9%

Gross Profit vs competitors

How MGNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +16.2% is the 4th highest of 10, against a peer median of -99.8%.
  • Gross profit amounts to 69.9% of revenue for MGNX, versus a peer median of 99.9%.
MGNX Competitors
Gross Profit for MGNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M USD+16.2%-9.3%69.9%
COYACoya Therapeutics, Inc.LTM Mar 2026$7.92M USD+177.2%—99.8%
OVIDOvid Therapeutics Inc.LTM Mar 2026$7.09M USD+1193.2%+66.6%99.5%
CNTBConnect Biopharma Holdings LimitedFY2025$64K USD-99.8%—100.0%
WHWKWhitehawk Therapeutics IncLTM Mar 2026-$5K USD+100.0%——
CNTXContext Therapeutics Inc.LTM Mar 2026-$40.17K USD———
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026-$121K USD+2.4%-83.1%—
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$151K USD-100.6%——
CLNNClene Inc.LTM Mar 2026-$244K USD-188.4%-29.4%182.1%
STTKShattuck Labs, Inc.LTM Mar 2026-$820K USD-146.7%—82.0%
IFRXInflaRx N.V.LTM Mar 2026-€7.23M EUR-142.9%—24646.3%
Peer median (excluding MGNX) —-99.8%-29.4%99.9%

Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.64M150.02M57.19M148.34M149.5M
Cost of Revenue2.65M7.38M8.22M12.3M43.18M
Gross Profit72.99M142.63M48.97M136.04M106.32M
Gross Margin96.5%95.1%85.6%91.7%71.1%
Research & Development214.58M207.03M166.58M177.19M140M
Selling, General & Admin63.01M58.95M52.19M71.05M39.16M
Operating Expenses275.79M264.05M217.22M246.62M179.16M
Depreciation & Amortization11.26M11.87M9.65M7.54M7.17M
EBITDA(190.86M)(107.89M)2.02M(57.37M)(59.61M)
EBITDA Margin-252.3%-71.9%3.5%-38.7%-39.9%
Operating Income(202.8M)(121.42M)(168.24M)(110.58M)(72.84M)
Operating Margin-268.1%-80.9%-294.2%-74.5%-48.7%
Interest Income680K1.7M9.69M9.42M3.4M
Interest Expense001.43M1.12M8.51M
Other Income / Expenses680K1.66M159.19M44.56M(2.45M)
Income Before Tax(202.12M)(119.76M)(9.06M)(66.02M)(75.29M)
Pre-Tax Margin-267.2%-79.8%-15.8%-44.5%-50.4%
Income Tax Expense000944K(672K)
Net Income(202.12M)(119.76M)(9.06M)(66.97M)(74.62M)
Net Margin-267.2%-79.8%-15.8%-45.1%-49.9%
EPS (Basic)(3.18)(1.95)(0.15)(1.07)(1.18)
EPS (Diluted)(3.18)(1.95)(0.15)(1.07)(1.18)
Weighted Avg Shares59.94M61.41M61.93M62.62M63.16M
Weighted Avg Shares (Diluted)59.94M61.43M61.93M62.62M63.16M

MacroGenics, Inc.

NASDAQ:MGNX

Intrinsic Alpha fair value

Locked

Current Price

$1.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.